AGOMAB THERAPEUTICS NV

Insider buying surges at AgomAb Therapeutics, with CEO and CFO adding 21k shares. Investors see confidence amid a steep 40% YTD drop, but watch for clinical cues before betting on the biotech stock.

CEO Tim Jasper’s bulk buy of AGOMAB shares signals confidence amid a 40% price drop, hinting at upcoming clinical wins or a potential rebound.